Clover Health Investments (NASDAQ:CLOV – Get Free Report) and HeartSciences (NASDAQ:HSCS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Clover Health Investments and HeartSciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clover Health Investments | 1 | 3 | 1 | 0 | 2.00 |
| HeartSciences | 1 | 0 | 1 | 0 | 2.00 |
Clover Health Investments currently has a consensus price target of $3.82, suggesting a potential downside of 29.45%. HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 173.50%. Given HeartSciences’ higher probable upside, analysts clearly believe HeartSciences is more favorable than Clover Health Investments.
Insider & Institutional Ownership
Valuation and Earnings
This table compares Clover Health Investments and HeartSciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clover Health Investments | $1.92 billion | 1.48 | -$85.55 million | ($0.12) | -45.08 |
| HeartSciences | N/A | N/A | -$8.77 million | ($4.94) | -0.59 |
HeartSciences has lower revenue, but higher earnings than Clover Health Investments. Clover Health Investments is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Clover Health Investments has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500. Comparatively, HeartSciences has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
Profitability
This table compares Clover Health Investments and HeartSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clover Health Investments | -2.58% | -16.52% | -9.28% |
| HeartSciences | N/A | -333.50% | -140.18% |
Summary
Clover Health Investments beats HeartSciences on 7 of the 11 factors compared between the two stocks.
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
About HeartSciences
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.
